Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 3/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15387213 | 0.83 | CYP1A2 (0.50) | POLBPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13467663 | 0.79 | SLC29A1 (0.49) | POLBSMN1; SMN2LMNATP53NPC1 | |
| SCHEMBL15387122 | 0.76 | CDK1 (0.57) | POLBPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3739727 | 0.75 | SLC29A1 (0.54) | POLBADORA2AADORA3SMN1; SMN2LMNA | |
| SCHEMBL24197034 | 0.75 | ADORA2A (0.49) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| Hydrochloric Acid SCHEMBL27432781 | 0.75 | ADORA2A (0.56) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL20626388 | 0.75 | SLC29A1 (0.76) | ADORA2AADORA3ADORA1SMN1; SMN2LMNA | |
| SCHEMBL20626389 | 0.75 | SLC29A1 (0.76) | ADORA2AADORA3ADORA1SMN1; SMN2LMNA | |
| SCHEMBL14713425 | 0.75 | SLC29A1 (0.76) | ADORA2AADORA3ADORA1SMN1; SMN2LMNA | |
| SCHEMBL7744330 | 0.75 | SLC29A1 (0.76) | ADORA2AADORA3ADORA1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2022-10-18 | — | — | US | disclosed |
| WO-2021214315-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901154-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2021-10-27 | — | — | EP | disclosed |
| EP-2664619-B1 | Purine derivatives as tools for screening anti-Alzheimer compounds | MANROS THERAPEUTICS (FR) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | ADORA1, OXGR1, ADORA2A | POLB 2861/4885PI4KA 2655/4885PI4K2B 2557/4885 |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | TPMT, ADORA2A, PNP | POLB 1366/4885PI4KA 3956/4885PI4K2B 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.